Mark Parrish - Omnicell Independent Director
| OMCL Stock | USD 27.43 1.00 3.52% |
Director
Mr. Mark W. Parrish is an Independent Director of Omnicell Inc. Since August 2018, Mr. Parrish has served as Executive Chairman of TridentUSA Health Services, a provider of mobile Xray and laboratory services to the longterm care industry. From 2008 to August 2018, Mr. Parrish served as Chief Executive Officer of TridentUSA Health Services. In February 2019, TridentUSA Health Services filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Commencing in 1993, Mr. Parrish held management roles of increasing significance with Cardinal Health Inc. and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as a director of Mylan Inc., a global pharmaceutical company President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies and senior adviser to Frazier Healthcare Ventures, a healthcare oriented growth equity firm since 2013.
| Age | 62 |
| Tenure | 11 years |
| Address | 4220 North Freeway, Fort Worth, TX, United States, 76137 |
| Phone | 877 415 9990 |
| Web | https://www.omnicell.com |
Omnicell Management Efficiency
Return On Tangible Assets is expected to rise to -0.02 this year. Return On Capital Employed is expected to rise to -0.0099 this year. At this time, Omnicell's Intangible Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 297.7 M this year, although the value of Return On Tangible Assets are projected to rise to (0.02). Omnicell's management efficiency ratios could be used to measure how well Omnicell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Adrian Dillon | HealthEquity | 63 | |
| Joseph Impicciche | R1 RCM Inc | 60 | |
| Albert Zimmerli | R1 RCM Inc | 66 | |
| Barbara Mowry | National Research Corp | 70 | |
| Michael Leavitt | HealthEquity | 66 | |
| Debra McCowan | HealthEquity | 46 | |
| Bert Zimmerli | R1 RCM Inc | 65 | |
| Ian Sacks | R1 RCM Inc | 47 | |
| Michael Feiner | R1 RCM Inc | 75 | |
| Neal Moszkowski | R1 RCM Inc | 52 | |
| John Nunnelly | National Research Corp | 65 | |
| Ian Sacks | HealthEquity | 47 | |
| P Shastri | National Research Corp | 65 | |
| Donald Berwick | National Research Corp | 71 | |
| Alex Mandl | R1 RCM Inc | 74 | |
| Manu Rana | HealthEquity | 45 | |
| Evelyn Dilsaver | HealthEquity | 62 | |
| Kjersti Kanne | National Research Corp | N/A | |
| Jill Smith | R1 RCM Inc | 59 | |
| Brita Eilertsen | National Research Corp | 53 | |
| Charles Ditkoff | R1 RCM Inc | 55 | |
Management Performance
| Return On Equity | -0.0176 | ||||
| Return On Asset | -0.0061 |
Omnicell Leadership Team
Elected by the shareholders, the Omnicell's board of directors comprises two types of representatives: Omnicell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Omnicell. The board's role is to monitor Omnicell's management team and ensure that shareholders' interests are well served. Omnicell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Omnicell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Nemeth, Senior Relations | ||
| Sara Dalmasso, Senior International | ||
| Jorge Taborga, Executive Vice President - Engineering | ||
| Daniel Johnston, Chief Admin. Officer, Chief Legal Officer, Executive VP and Corporate Secretary | ||
| Minoo Mortazavi, Senior Operations | ||
| Joanne Bauer, Independent Director | ||
| Christopher Drew, Executive VP of Sales and Marketing | ||
| James Judson, Lead Independent Director | ||
| Bruce Smith, Director | ||
| Sara White, Independent Director | ||
| Nchacha Etta, Executive CFO | ||
| Randall Lipps, Executive Chairman, CEO and Pres | ||
| Scott Seidelmann, Executive Vice President and Chief Commercial Officer | ||
| Maximo Rocha, Senior Officer | ||
| Robin Seim, Executive VP for International and Global Quality and Manufacturing | ||
| Giri Chodavarapu, Senior Officer | ||
| Vance Moore, Independent Director | ||
| Joseph Spears, Principal Chief Accounting Officer | ||
| Mark Parrish, Independent Director | ||
| Vicki MacDevitt, Chief Staff | ||
| Randy Lindholm, Independent Director | ||
| Corey Manley, Executive Officer | ||
| Bruce Scott, Independent Director | ||
| David Vanella, Senior Regulatory | ||
| Roxanne Turner, Sr Officer | ||
| Gary Petersmeyer, Independent Director | ||
| Christine Mellon, Chief VP | ||
| Peter Kuipers, CFO, Executive Vice President | ||
| Brian Nutt, Chief VP | ||
| Nhat Ngo, Executive VP of Strategy and Bus. Devel. |
Omnicell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Omnicell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0176 | ||||
| Return On Asset | -0.0061 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 1.41 B | ||||
| Shares Outstanding | 45.92 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 98.60 % | ||||
| Number Of Shares Shorted | 2.37 M | ||||
| Price To Earning | 64.95 X |
Omnicell Investors Sentiment
The influence of Omnicell's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Omnicell. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Omnicell's public news can be used to forecast risks associated with an investment in Omnicell. The trend in average sentiment can be used to explain how an investor holding Omnicell can time the market purely based on public headlines and social activities around Omnicell. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Omnicell's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Omnicell's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Omnicell's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Omnicell.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Omnicell in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Omnicell's short interest history, or implied volatility extrapolated from Omnicell options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.Note that the Omnicell information on this page should be used as a complementary analysis to other Omnicell's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Omnicell Stock analysis
When running Omnicell's price analysis, check to measure Omnicell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omnicell is operating at the current time. Most of Omnicell's value examination focuses on studying past and present price action to predict the probability of Omnicell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omnicell's price. Additionally, you may evaluate how the addition of Omnicell to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Omnicell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.68) | Earnings Share (0.45) | Revenue Per Share 25.372 | Quarterly Revenue Growth (0.13) | Return On Assets (0.01) |
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.